Health TrialsbyHealthPanel

Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections

ConditionInvasive Fungal Infections
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age12+
SponsorBasilea Pharmaceutica

About this trial

The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Fosmanogepix solution for infusion

    Drug

    Fosmanogepix solution for infusion, 20 mg/mL for intravenous administration

  • Fosmanogepix 400 mg tablets

    Drug

    Fosmanogepix 400 mg tablets for oral administration

Treatment groups

No treatment groups listed

Trial outcomes

This trial has no outcomes listed.

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Basilea Pharmaceutica

Lead sponsor

Source ClinicalTrials.gov
Apply now